Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$883.20 USD
-7.48 (-0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $881.43 -1.77 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 3,953.60 | 4,338.40 | 8,075.30 | 3,513.20 | 2,115.80 |
Depreciation/Amortization & Depletion | 421.00 | 341.40 | 286.20 | 235.90 | 210.30 |
Net Change from Assets/Liabilities | -94.10 | -243.30 | -1,916.50 | -1,503.60 | -200.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 313.50 | 578.40 | 636.30 | 372.60 | 304.40 |
Net Cash From Operating Activities | 4,594.00 | 5,014.90 | 7,081.30 | 2,618.10 | 2,430.00 |
Property & Equipment | -718.60 | -590.10 | -551.90 | -614.60 | -429.60 |
Acquisition/ Disposition of Subsidiaries | -54.90 | -230.30 | 0.00 | 0.00 | 0.00 |
Investments | -2,203.80 | -1,937.40 | -4,832.80 | 544.00 | -1,598.20 |
Other Investing Activities | -207.80 | -1,026.80 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -3,185.10 | -3,784.60 | -5,384.70 | -70.60 | -2,027.80 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1,790.10 | -1,009.00 | -1,005.80 | -3,952.40 | -252.10 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 1,981.90 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -1,790.10 | -1,009.00 | -1,005.80 | -1,970.50 | -252.10 |
Effect of Exchange Rate Changes | -0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -381.60 | 221.30 | 690.80 | 577.00 | 150.10 |
Cash at Beginning of Period | 3,119.40 | 2,898.10 | 2,207.30 | 1,630.30 | 1,480.20 |
Cash at End of Period | 2,737.80 | 3,119.40 | 2,898.10 | 2,207.30 | 1,630.30 |
Diluted Net EPS | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 |
Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 3,953.60 | 2,794.00 | 1,786.20 | 817.80 |
Depreciation/Amortization & Depletion | NA | 421.00 | 308.00 | 202.60 | 99.50 |
Net Change from Assets/Liabilities | NA | -94.10 | -32.70 | 159.60 | 240.90 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 313.50 | 435.00 | 241.60 | 209.40 |
Net Cash From Operating Activities | NA | 4,594.00 | 3,504.30 | 2,390.00 | 1,367.60 |
Property & Equipment | NA | -718.60 | -467.20 | -291.20 | -178.20 |
Acquisition/ Disposition of Subsidiaries | NA | -54.90 | -51.10 | 0.00 | 0.00 |
Investments | NA | -2,203.80 | -2,454.90 | -2,209.60 | 43.40 |
Other Investing Activities | NA | -207.80 | -145.70 | -121.80 | -100.90 |
Net Cash from Investing Activities | NA | -3,185.10 | -3,118.90 | -2,622.60 | -235.70 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -1,790.10 | -1,344.00 | -936.70 | -322.50 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -1,790.10 | -1,344.00 | -936.70 | -322.50 |
Effect of Exchange Rate Changes | NA | -0.40 | -0.60 | -0.40 | 0.00 |
Net Change In Cash & Equivalents | NA | -381.60 | -959.20 | -1,169.70 | 809.40 |
Cash at Beginning of Period | NA | 3,119.40 | 3,119.40 | 3,119.40 | 3,119.40 |
Cash at End of Period | NA | 2,737.80 | 2,160.20 | 1,949.70 | 3,928.80 |
Diluted Net EPS | NA | 10.21 | 8.89 | 8.50 | 7.17 |